KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2025)

Rigel Pharmaceuticals has reported Gross Margin over the past 8 years, most recently at 91.47% for Q4 2025.

  • Quarterly results put Gross Margin at 91.47% for Q4 2025, up 152.0% from a year ago — trailing twelve months through Dec 2025 was 93.33% (up 373.0% YoY), and the annual figure for FY2025 was 93.33%, up 373.0%.
  • Gross Margin for Q4 2025 was 91.47% at Rigel Pharmaceuticals, down from 93.16% in the prior quarter.
  • Over the last five years, Gross Margin for RIGL hit a ceiling of 99.61% in Q1 2021 and a floor of 85.49% in Q3 2024.
  • Median Gross Margin over the past 5 years was 95.79% (2025), compared with a mean of 95.01%.
  • Biggest five-year swings in Gross Margin: plummeted -1000bps in 2024 and later skyrocketed 767bps in 2025.
  • Rigel Pharmaceuticals' Gross Margin stood at 97.61% in 2021, then rose by 2bps to 99.33% in 2022, then fell by -10bps to 89.41% in 2023, then grew by 1bps to 89.95% in 2024, then increased by 2bps to 91.47% in 2025.
  • The last three reported values for Gross Margin were 91.47% (Q4 2025), 93.16% (Q3 2025), and 95.57% (Q2 2025) per Business Quant data.